In recurrent or metastatic HNSCC treated with Cetuximab, an EGFR inhibitor, low PTEN expression was associated with worse overall survival (hazard ratio 2.27) [68]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.